A new combo may benefit patients with HER-2 positive metastatic breast cancer, according to a new study.
HER2-Positive Breast Cancer
A new analysis looked at how dose interruptions or reductions of ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes.
Researchers looked at the characteristics of breast cancer found in patients under 40 years old.
A phase III trial tested trastuzumab emtansine (T-DM1) with or without pertuzumab in patients with HER2-positive metastatic breast cancer.
Researchers compared invasive disease-free survival rates in patients with breast cancer who took nanoparticle albumin-bound (NAB)-paclitaxel compared with those who took solvent-based (sb)-paclitaxel.
A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients.
Novel research suggests that using a nano-molecularly imprinted polymer may offer a unique and effective way to treat HER2+ breast cancer.
Researchers tested the novel antibody-drug conjugate trastuzumab duocarmazine in patients with heavily pretreated HER2-expressing metastatic cancers, including breast cancer.
After more than 7 years of follow-up, the phase III PHARE trial failed to show that 6 months of adjuvant trastuzumab therapy was noninferior to 12 months in patients with HER2+ early breast cancer.
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.